Beyond RAS and BRAF: a target rich disease that is ripe for picking

Por Friedrich, Tyler, Leong, Stephen, Lieu, Christopher H.
Publicado no J Gastrointest Oncol (2016)

From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development

Por Lieu, Christopher H., Tan, Aik-Choon, Leong, Stephen, Diamond, Jennifer R., Eckhardt, S. Gail
Publicado em 2013

Targeting the WNT Signaling Pathway in Cancer Therapeutics

Por Tai, David, Wells, Keith, Arcaroli, John, Vanderbilt, Chad, Aisner, Dara L., Messersmith, Wells A., Lieu, Christopher H.
Publicado no Oncologist (2015)

Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer

Por Tran, Ben, Kopetz, Scott, Tie, Jeanne, Gibbs, Peter, Jiang, Zhi-Qin, Lieu, Christopher H, Agarwal, Atin, Maru, Dipen M, Sieber, Oliver, Desai, Jayesh
Publicado no Cancer (2011)

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

Por Lieu, Christopher H., Tran, Hai, Jiang, Zhi-Qin, Mao, Muling, Overman, Michael J., Lin, E., Eng, Cathy, Morris, Jeffrey, Ellis, Lee, Heymach, John V., Kopetz, Scott
Publicado em 2013

Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program

Por Lieu, Christopher H., Renfro, Lindsay A., de Gramont, Aimery, Meyers, Jeffrey P., Maughan, Timothy S., Seymour, Matthew T., Saltz, Leonard, Goldberg, Richard M., Sargent, Daniel J., Eckhardt, S. Gail, Eng, Cathy
Publicado no J Clin Oncol (2014)

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts

Por Lieu, Christopher H., Klauck, Peter J., Henthorn, Patrick K., Tentler, John J., Tan, Aik-Choon, Spreafico, Anna, Selby, Heather M., Britt, Blair C., Bagby, Stacey M., Arcaroli, John J., Messersmith, Wells A., Pitts, Todd M., Eckhardt, S. Gail
Publicado no Oncotarget (2015)

Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers

Por Kessler, Elizabeth R, Eckhardt, S Gail, Pitts, Todd M, Bradshaw-Pierce, Erica L, O'byrant, Cindy L, Messersmith, Wells A, Nallapreddy, Sujatha, Weekes, Colin, Spratlin, Jennifer, Lieu, Christopher H, Kane, Madeleine A, Eppers, Sarah, Freas, Elizabeth, Leong, Stephen
Publicado no Invest New Drugs (2015)